Prevents bronchospasm. ANDA 207820, held by Sun Pharm. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 207820 (Levalbuterol Hydrochloride), held by Sun Pharm, was first approved by FDA on Nov 5, 2018, with 1 approved supplement and 0 published complete response letters.
Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2018 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Discontinued |
| Dec 20, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters